Visa Plans New Global Technology and Product Hub in Poland to Support 24/7 Development Model for Innovation
23.5.2023 10:00:00 EEST | Business Wire | Press release
Visa Inc. (NYSE: V), a global leader in digital payments, today announced that it plans to open a new global Technology and Product Hub in Poland that will be the first of its kind for Visa in Central and Eastern Europe. The Hub will house as many as 1,500 new tech and product hires over the next few years, as Visa invests worldwide to support its 24/7 development model for innovation and drives continued rapid growth in digital commerce and payments.
“Poland’s highly skilled workforce and vibrant IT sector make it an ideal location for us to recruit and collaborate with partners and businesses to develop new payment solutions,” said Rajat Taneja, President, Technology, Visa. “The next wave of our product and innovation roadmap is even more exciting as we focus on the next generation of AI, cybersecurity and the resilience and availability of our network for all who depend on it.”
Poland will serve as Visa’s fifth major strategic global Technology and Product Hub. As a growing location for top technology talent, it builds on Visa’s commitment to innovation and investment in the European region, and in Poland, in particular. Visa will find new ways to harness emerging talent in the region, accelerate product development and innovate at scale to bring value to consumers, clients, buyers and sellers around the world.
“As a global company that does business in more than 200 countries and territories, it is important to us to invest in local talent, creating regional tech hubs that allow us to serve our global customer base better than ever before,” said Charlotte Hogg, CEO, Visa, Europe. “We are committed to diversity and inclusion and ensuring that as Visa grows, it reflects the wide range of perspectives that make up the communities where we live and work. In Poland, this will mean bringing on board a diverse talent pool and welcoming talent from Ukraine and other parts of the region.”
“It is exceptionally good news that Visa, with its unique global experience and know-how, has chosen our country out of all possible locations, thus building Poland's position as the best place for investments in the new technology sector,” said Prime Minister of Poland, Mateusz Morawiecki. “Some of the factors that pointed to Poland as a location for this investment were the high qualifications of our IT staff and the significant pool of talent on the labor market. We have great potential to bring highly innovative investments to our country."
Visa has been at the forefront of digital payments for more than 60 years, operating in Poland since 1995. The first payment card in Poland was a Visa card and since the early digital days, Visa innovations have underpinned many of the ways that consumers and merchants pay and are paid. With Visa as a driving force in digital payments, Poland became the first market in the world to achieve 100% contactless availability.
Visa recognizes the critical role that digital skills play in the modern economy and is committed to supporting the EU’s efforts to build a more competitive and digitally savvy workforce.1 This investment underscores Visa’s pledge to promote digital inclusion and empower individuals to thrive in the digital age.
More details on Visa’s new global Technology and Product Hub will be shared in the coming months. Open roles in Poland can be found here.
About Visa Inc.
Visa (NYSE: V) is a world leader in digital payments, facilitating payments transactions between consumers, merchants, financial institutions and government entities across more than 200 countries and territories. Our mission is to connect the world through the most innovative, convenient, reliable and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at Visa.com.
1 Through the Digital Decade the EU aims to ensure that 20 million ICT specialists are in employment in the EU by 2030. https://ec.europa.eu/commission/presscorner/detail/en/ip_23_2246
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005524/en/
Contact information
Krzysztof Pilaszek
pilaszek@visa.com
+48663033839
Isobel Bradshaw
bradshai@visa.com
+44 7812 384276
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom